logo.jpg
US Transdermal Patch Drug Delivery Market Size Clinical Trials Forecast 2026
November 18, 2021 08:14 ET | KuicK Research
Delhi, Nov. 18, 2021 (GLOBE NEWSWIRE) -- US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026 Report Highlights: US Transdermal Patch Market InsightUS Transdermal Patch...
IGX Bigger Size Logo.jpg
IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention
May 23, 2019 08:00 ET | IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it will be joining the Quebec...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
July 09, 2018 06:55 ET | Zynerba Pharmaceuticals, Inc.
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba...
CFN LOGO.png
NanoSphere Health Sciences: Advancing the Industry with Breakthrough Cannabinoid Delivery -- CFN Media
May 10, 2018 08:45 ET | CFN Media
SEATTLE, May 10, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an...
CFN LOGO.png
NanoSphere Health Sciences Achieves Landmark Patent -- CFN Media
April 10, 2018 08:30 ET | CFN Media; NanoSphere Health Sciences Inc.
SEATTLE, April 10, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of...
Agile_Logo-color on white.jpg
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
March 14, 2018 07:45 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
January 03, 2018 16:30 ET | Zynerba Pharmaceuticals, Inc.
 - Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30...
Agile_Logo-color on white.jpg
Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
October 10, 2017 18:38 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today hosted the Company’s first analyst day in New York City to showcase its...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
September 28, 2017 06:30 ET | Zynerba Pharmaceuticals, Inc.
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa., Sept. 28, 2017 ...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...